Contact this trialFirst, we need to learn more about you.
MDM2 Inhibitor
KRT-232 for Small Cell Lung Cancer
Recruiting1 awardPhase 2
Nashville, Tennessee
This trial will assess the safety and efficacy of KRT-232 in treating patients with small cell lung cancer that has progressed after prior treatment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.